XLIMus drug eluting stent : A randomIzed controlled Trial to assess endothelialization. The XLIMIT trial
Testa, Luca (IRCCS Policlinico S. Donato)
Pero, Gaetano (IRCCS Policlinico S. Donato)
Bollati, Mario (IRCCS Policlinico S. Donato)
Matteo, Casenghi (IRCCS Policlinico S. Donato)
Popolo Rubbio, Antonio (IRCCS Policlinico S. Donato)
Cuman, Magdalena (IRCCS Policlinico S. Donato)
Moreno, Raul (Hospital Universitario La Paz (Madrid))
Serra, Antoni (Institut d'Investigació Biomèdica Sant Pau)
Gomez, Josep Antoni (Hospital Universitari de Bellvitge)
Bedogni, Francesco (IRCCS Policlinico S. Donato)
Universitat Autònoma de Barcelona

Data:	2019
Resum:	Thin strut 3rd generation drug eluting stents offer the potential advantage over the previous generation of better technical performance and reduced neointimal proliferation parameters, which are linked to mid and late term device failure. To evaluate the performance of the Xlimus sirolimus-eluting stent (SES) against the Synergy everolimus-eluting stent (EES) in terms of device reendothelialization in patients undergoing PCI for coronary artery disease (CAD). Methods: XLIMIT is a multicenter randomized controlled trial targeting 180 patients requiring percutaneous coronary interventions (PCI). Patients will be treated with Xlimus SES or Synergy EES implantation and randomization will be performed in a 2:1 ratio. The primary endpoint will be the reendothelialization grade of the Xlimus stent in terms of strut coverage and neointimal hyperplasia volume as compared to Synergy. Secondary endpoints will be represented by clinical and procedural outcomes. The first patient was enrolled on February 2019. A clearer understanding of the endothelialization process of new generation DES could significantly impact the treatment with dual antiplatelet therapy in the future. Moreover, although not powered for clinical end-points, the XLIMIT trial will provide randomized data in a population with minimal exclusion criteria. Trial registration: ClinicalTrials. gov Identifier: NCT03745053. Registered on November 19, 2018.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Clinical trials ; Coronary artery disease ; Drug-eluting stent
Publicat a:	International journal of cardiology. Heart & vasculature, Vol. 23 (june 2019) , p. 100363, ISSN 2352-9067

DOI: 10.1016/j.ijcha.2019.100363
PMID: 31061876

5 p, 609.6 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats